Efficacy and Safety of Ixazomib plus Lenalidomidedexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) by Cytogenetic Risk Status in the Global Phase Iii Tourmaline-Mm1 Study.

AuthID
P-00R-HSN
20
Author(s)
Richardson, PG
·
Avet Loiseau, H
·
Palumbo, A
·
Nagler, A
·
Ganly, P
·
Ben Yehuda, D
·
Miguel, JS
·
Rajkumar, SV
·
Langer, C
·
Berg, D
·
Lin, JC
·
Van De Velde, H
·
di Baccot, A
·
Moreau, P
Tipo de Documento
Abstract
Year published
2016
Publicado
in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X
Volume: 34, Número: 15
Conference
Annual Meeting of the American-Society-Of-Clinical-Oncology (Asco), Date: JUN 03-07, 2016, Location: Chicago, IL, Patrocinadores: Amer Soc Clin Oncol
Indexing
Publication Identifiers
Wos: WOS:000404711505174
Source Identifiers
ISSN: 0732-183X
Export Publication Metadata
Info
At this moment we don't have any links to full text documens.